{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:03:46Z","timestamp":1771927426506,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is a serious complication of chronic obstructive pulmonary disease (COPD) that markedly worsens functional capacity and prognosis. Fasudil, a selective Rho-kinase inhibitor, has shown vasodilatory and vascular-protective effects; however, its therapeutic value in COPD-associated PAH has not been systematically quantified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of the study was to evaluate the efficacy of fasudil as an adjunctive therapy for COPD patients with PAH through a systematic review and meta-analysis of randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eight electronic databases were searched from inception to April 2024 for RCTs comparing fasudil plus conventional therapy with conventional therapy alone. Primary outcomes included overall treatment effectiveness and pulmonary artery systolic pressure (PASP). Secondary outcomes were blood oxygen saturation (SaO\u2082), arterial oxygen tension (PaO\u2082), and 6-min walk distance (6MWT). Data were pooled using fixed- or random-effects models according to heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 11 RCTs involving 865 participants met the inclusion criteria. Fasudil significantly increased the overall effective rate (risk ratio\u202f=\u202f1.18, 95% CI\u202f=\u202f1.05\u20131.31,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004) and reduced PASP (mean difference\u202f=\u202f\u22129.42\u202fmmHg, 95% CI\u202f=\u202f\u221210.73 to \u22128.12,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) with negligible heterogeneity. Chronic treatment (\u22652\u202fweeks) improved SaO\u2082 (MD\u202f=\u202f3.56, 95% CI 1.73\u20135.40), whereas single-dose administration had a minimal effect. PaO\u2082 increased modestly (MD\u202f=\u202f2.19\u202fmmHg, 95% CI\u202f=\u202f0.84\u20133.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.002). Functional capacity improved substantially, with a 51.96-m gain in 6MWT distance (95% CI\u202f=\u202f36.84\u201367.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), exceeding the minimal clinically important difference.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Fasudil confers consistent short-term benefits in COPD-related PAH, significantly lowering pulmonary pressures and enhancing oxygenation and exercise tolerance. While the included studies were of moderate methodological quality and limited to Chinese settings, the pooled evidence supports fasudil as a promising adjunct for managing COPD-associated PAH. Larger, multicenter RCTs with longer follow-up are warranted to confirm its long-term efficacy and safety. The short follow-up (maximum 4\u202fweeks) limits insights into sustained benefits or progression; long-term trials are essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1723597","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:12:26Z","timestamp":1769411546000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of fasudil in COPD-associated pulmonary arterial hypertension: meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Pei","family":"Shu","sequence":"first","affiliation":[{"name":"Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]},{"name":"The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorui","family":"Xu","sequence":"additional","affiliation":[{"name":"First Clinical College of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional and Western Medicine, Liaoning Cancer Hospital and Institute","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni-Ni","family":"Qu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive Lung disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0261692","DOI":"10.1371\/journal.pone.0261692","article-title":"Epidemiological evidence relating risk factors to chronic obstructive pulmonary disease in China: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2021","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agusti","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3390\/ph14100979","article-title":"Mechanisms, pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease","volume":"14","author":"Rodrigues","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-021-01812-x","article-title":"The effects of traffic-related air pollutants on chronic obstructive pulmonary disease in the community-based general population","volume":"22","author":"Hsu","year":"2021","journal-title":"Respir Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"111739","DOI":"10.1016\/j.envres.2021.111739","article-title":"Occupational exposure to particles and increased risk of developing chronic obstructive pulmonary disease (COPD): a population-based cohort study in Stockholm","volume":"200","author":"Grahn","year":"2021","journal-title":"Sweden Environ Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.chest.2022.01.031","article-title":"Severe pulmonary hypertension in COPD: impact on survival and diagnostic approach","volume":"162","author":"Kovacs","year":"2022","journal-title":"Chest"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e011343","DOI":"10.1161\/JAHA.118.011343","article-title":"Repurposing medications for treatment of pulmonary arterial hypertension: what's old is new again","volume":"8","author":"Prins","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1183\/23120541.00348-2021","article-title":"Treatment of pulmonary hypertension associated with COPD: a systematic review","volume":"8","author":"Arif","year":"2022","journal-title":"ERJ Open Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2147\/VHRM.S4711","article-title":"RhoA\/rho-kinase signaling: a therapeutic target in pulmonary hypertension","volume":"5","author":"Barman","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"115321","DOI":"10.1016\/j.bcp.2022.115321","article-title":"A current overview of RhoA, RhoB, and RhoC functions in vascular biology and pathology","volume":"206","author":"Eckenstaler","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/a-1879-3111","article-title":"The therapeutic role of rho kinase inhibitor, Fasudil, on pulmonary hypertension; a systematic review and Meta-analysis","volume":"73","author":"Abedi","year":"2023","journal-title":"Drug Res (Stuttg)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/DDDT.S297500","article-title":"Fasudil dichloroacetate alleviates SU5416\/hypoxia-induced pulmonary arterial hypertension by ameliorating dysfunction of pulmonary arterial smooth muscle cells","volume":"15","author":"Liu","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3233\/CH-200892","article-title":"Concealed role of red blood cells in pathogenesis of pulmonary arterial hypertension: decreased red blood cell nitric oxide generation and effect of rho-kinase inhibitor fasudil","volume":"76","author":"Basarici","year":"2020","journal-title":"Clin Hemorheol Microcirc"},{"key":"ref15","first-page":"2429","article-title":"Effects of Fasudil on MMP-9 and platelet indices in patients with COPD complicated with pulmonary arterial hypertension","volume":"34","author":"Zhou","year":"2021","journal-title":"Med Theory Pract"},{"key":"ref16","first-page":"1213","article-title":"Effects of Fasudil on pulmonary function and VEGF in patients with AECOPD complicated with PAH","volume":"27","author":"Zeng","year":"2017","journal-title":"Med J Southwest China"},{"key":"ref17","first-page":"90","article-title":"Clinical efficacy of Fasudil combined with salmeterol and fluticasone propionate powder inhalant in patients with COPD complicated with PAH","volume":"26","author":"Lu","year":"2017","journal-title":"Chin J Cardiovasc Rehabil Med"},{"key":"ref18","first-page":"45","article-title":"Observation on the effect of Fasudil hydrochloride injection in the treatment of chronic obstructive pulmonary disease complicated with pulmonary arterial hypertension","volume":"5","author":"Liu","year":"2021","journal-title":"Mod Med Health Res (Electronic Ed)"},{"key":"ref19","first-page":"121","article-title":"Efficacy and safety evaluation of rosuvastatin combined with Fasudil in patients with chronic obstructive pulmonary disease complicated with pulmonary arterial hypertension","volume":"14","author":"Li","year":"2024","journal-title":"China Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1183\/09031936.00095211","article-title":"Effects of fasudil in patients with high-altitude pulmonary hypertension","volume":"39","author":"Kojonazarov","year":"2012","journal-title":"Eur Respir J"},{"key":"ref21","first-page":"2176","article-title":"Clinical study of Fasudil in the treatment of chronic obstructive pulmonary disease complicated with pulmonary arterial hypertension","volume":"37","author":"Hua","year":"2016","journal-title":"Jilin Med J"},{"key":"ref22","first-page":"39","article-title":"Randomized controlled study of Fasudil in elderly patients with chronic obstructive pulmonary disease complicated with pulmonary arterial hypertension","volume":"27","author":"Gao","year":"2017","journal-title":"China Healthcare Nutr"},{"key":"ref23","first-page":"1808","article-title":"Clinical study on the efficacy of Fasudil injection in the treatment of pulmonary arterial hypertension","volume":"21","author":"Jiang","year":"2016","journal-title":"J Clin Pulm Med"},{"key":"ref24","first-page":"97","article-title":"Effects of Fasudil in the treatment of chronic obstructive pulmonary disease complicated with pulmonary arterial hypertension on NT-proBNP","volume":"28","author":"Meng","year":"2016","journal-title":"JPLA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2014.09.101","article-title":"Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study","volume":"177","author":"Jiang","year":"2014","journal-title":"Int J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"CD013817","DOI":"10.1002\/14651858.CD013817.pub2","article-title":"Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension","volume":"2022","author":"Clement Freiberg","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17425247.2020.1729119","article-title":"Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension","volume":"17","author":"Keshavarz","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"121792","DOI":"10.1016\/j.ijpharm.2022.121792","article-title":"Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial hypertension","volume":"621","author":"Dhoble","year":"2022","journal-title":"Int J Pharm"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/eurheartj\/ehad005","article-title":"Corrigendum to: 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European reference network on rare respiratory diseases (ERN-LUNG)","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"108749","DOI":"10.1016\/j.cbi.2019.108749","article-title":"Protective effects of 18beta-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of rho a\/rho kinsase pathway","volume":"311","author":"Zhang","year":"2019","journal-title":"Chem Biol Interact"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.bmcl.2019.05.006","article-title":"Fasudil dichloroacetate (FDCA), an orally available agent with potent therapeutic efficiency on monocrotaline-induced pulmonary arterial hypertension rats","volume":"29","author":"Qi","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/1358863X12459790","article-title":"Inhibition of rho-kinase attenuates endothelial\u2013leukocyte interaction during ischemia\u2013reperfusion injury","volume":"17","author":"Wang","year":"2012","journal-title":"Vasc Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jchf.2023.08.030","article-title":"Effects of a rho-kinase inhibitor in patients with pulmonary hypertension due to left heart disease","volume":"12","author":"Ishiyama","year":"2024","journal-title":"JACC Heart Fail"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.RES.0000111804.34509.94","article-title":"Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats","volume":"94","author":"Abe","year":"2004","journal-title":"Circ Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5993\/AJHB.31.s1.16","article-title":"Integrating literacy, culture, and language to improve health care quality for diverse populations","volume":"31","author":"Andrulis","year":"2007","journal-title":"Am J Health Behav"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1723597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:11:28Z","timestamp":1771924288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1723597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1723597"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1723597","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1723597"}}